ELI LILLY & Co
Close on Nov 2, 2026Market cap $1.33TP/E 45.8Yield 0.44%
Eli Lilly COVID-19 Antibodies by Quarter
COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M)
Eli Lilly COVID-19 Antibodies: $0M in Q4 2023, down 100.0% from a year earlier. That is the lowest of the 16 quarters on record here. No newer figure appears in the documents we track.
Where the Q4 2023 figure comes from
Calculated from reported figures: Q4 = full year (10-K) − nine months (10-Q)
Source: Form 10-K (filed 2025-02-19) ↗
Reported in Form 10-Q / 10-K Note 2 & MD&A (legacy separate product disclosure prior to FY2025 reorganization).
Quarterly history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue ($M) [legacy separate disclosure] ($M) | Year on year | Source |
|---|---|---|---|---|
| Q4 2023 | Dec 31, 2023 | 0 | -100.0% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2023 | Sep 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2023 | Jun 30, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2023 | Mar 31, 2023 | 0 | -100.0% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2022 | Dec 31, 2022 | 30 | -97.2% | Form 10-K (filed 2025-02-19) ↗ |
| Q3 2022 | Sep 30, 2022 | 387 | +78.1% | Form 10-Q (filed 2023-11-02) ↗ |
| Q2 2022 | Jun 30, 2022 | 129 | -13.3% | Form 10-Q (filed 2023-08-08) ↗ |
| Q1 2022 | Mar 31, 2022 | 1,470 | +81.5% | Form 10-Q (filed 2023-04-27) ↗ |
| Q4 2021 | Dec 31, 2021 | 1,060 | +21.7% | Form 10-K (filed 2024-02-21) ↗ |
| Q3 2021 | Sep 30, 2021 | 217 | – | Form 10-Q (filed 2022-11-01) ↗ |
| Q2 2021 | Jun 30, 2021 | 149 | – | Form 10-Q (filed 2022-08-04) ↗ |
| Q1 2021 | Mar 31, 2021 | 810 | – | Form 10-Q (filed 2022-04-29) ↗ |
| Q4 2020 | Dec 31, 2020 | 871 | – | Form 10-K (filed 2023-02-22) ↗ |
| Q3 2020 | Sep 30, 2020 | 0 | – | Form 10-Q (filed 2021-10-27) ↗ |
| Q2 2020 | Jun 30, 2020 | 0 | – | Form 10-Q (filed 2021-08-03) ↗ |
| Q1 2020 | Mar 31, 2020 | 0 | – | Form 10-Q (filed 2021-04-30) ↗ |
Breakdown
What makes up COVID-19 Antibodies
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — U.S. revenue ($M) [legacy]0 · Q4 2023
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Outside U.S. revenue ($M) [legacy]0 · Q4 2023
- COVID-19 Antibodies (bamlanivimab / etesevimab / bebtelovimab) — Worldwide revenue YoY (%) [legacy]-100.0% · Q4 2023
Cite this data
StockData. (2026). Eli Lilly COVID-19 Antibodies ($M), quarterly Q1 2020–Q4 2023 [Data set]. Compiled from Eli Lilly SEC filings and investor materials. https://stockdatahq.com/stocks/lly/kpis/med-covid19antibodies-ww
See every metric in the Eli Lilly KPI table. Data updated Oct 25, 2026.